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Introduction:

52
A variety of novel drug carrier systems have recently been proposed to improve the 53 bioavailability and release of drugs [1] . These systems are aimed at maintaining local effects and desirable advantageous such as low toxicity of constituents, and the ability to protect the 62 incorporated drug from degradation by immobilization in the solid/liquid particle matrix [14] .
63
Moreover, NLCs have overcome problems associated with SLNs, including limited drug loading, 64 risk of gelation, and drug leakage during storage caused by lipid polymorphism [14] .
65
Fluconazole (FLZ), a first-generation triazole, is a broad-spectrum anti-fungal agent that inhibits 66 cytochrome P450-dependent 14α-lanosterol demethylation, a vital step in cell membrane 67 ergosterol synthesis [15] . Fluconazole is active against all Candida species except for C. 68 glabrata, which has acquired resistance to fluconazole, and C. krusie, which is resistant to the 69 drug intrinsically [16, 17] . Despite its advantageous pharmacological activity, FLZ can cause 70 several clinically significant side effects, including headache, hives, itching or skin rash, 71 abdominal pain, and hematemesis [3] . While the prevalence and severity of side effects may be 72 decreased by lowering the dose of FLZ, clinical efficacy may be reduced and resistance 73 increased through this approach. This problem is important because FLZ is currently used for Instruments, UK) was used to determine the particle size, and to profile the size distribution determined by HPLC and the experiment was conducted in triplicate.
158
The drug entrapment efficiency (EE%) was calculated from Equation 1, where Wi and Wf were 159 the amount of drug added in the formulation and amount of drug in the supernatant, respectively. was then made using a 1:10 dilution followed by a 1:100 dilution of the stock suspension with
207
RPMI medium, which resulted in two times test inoculums (1 × 10 3 to 5 × 10 3 CFU/ml). 
Characterization of SLNs
235
The particle sizes, zeta potential, and entrapment efficiency of the developed SLNs and NLCs
236
are shown in Table 2 . The FLZ-NLC-6 was selected as the best formulation because of its small 237 particle size (126.4 ± 15.2 nm), relatively high zeta potential (-35.1 ± 3.0) and good EE% (93.6 ± 238 3.5) (P < 0.05). Furthermore, it was observed that the average particle size decreased with an probably be considered as another key factor for the reduction in particle size.
246
It has also been reported that the concentration of oleic acid had no significant effect on NLC The drug release profile of the FLZ-NLCs is shown in Figure 1A . In this study, the FLZ-NLCs isolates, 39 isolates demonstrated high MIC values (≥64 µg/ml) against FLZ (Table 3 and Figure   273 2), among which, 14 isolates were C. albicans (35%), 13 were C. glabrata (33%), 9 were C. 274 parapsilosis (23%), and 3 were C. krusei (7.7%). No statistically significant differences were 275 seen among MICs for FLZ-susceptible Candida species. Table 3 resulted in a significant decrease in MIC (P < 0.05).
292
To the best of our knowledge, there are few documented reports about the synthesis of FLZ-
293
NLCs. Thus, studying their effect on a large number of Candida species is novel. 
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